Apichope Pharmaceutical's Subsidiary Sees Clinical Trial Application for Novel Drug APH03867 Accepted

Stock News

Jun 18

An announcement from Apichope Pharmaceutical Group Co.,Ltd. (ASX: 300723) reveals that its wholly-owned subsidiary, Guangzhou Apichope Pharmaceutical Co., Ltd., has received acceptance for its clinical trial application for the self-developed novel drug APH03867 tablets from the National Medical Products Administration, along with the corresponding acceptance notice.

APH03867 tablets are a new type of oral, non-peptide small molecule URAT1 inhibitor (Urate Transporter 1) independently developed by the company. By inhibiting the activity of URAT1 in the kidneys, the drug blocks the reabsorption of uric acid in the renal tubules, increases uric acid excretion, and effectively reduces serum uric acid levels. It is intended for the improvement of hyperuricemia and gout symptoms.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1177714897"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177714897\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177714897?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 12:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177714897","market":"sg","top_or_hot":-1,"title":"Apichope Pharmaceutical's Subsidiary Sees Clinical Trial Application for Novel Drug APH03867 Accepted","media":"Stock News","content":"<p>An announcement from <b>Apichope Pharmaceutical Group Co.,Ltd.</b> (<b>ASX: 300723</b>) reveals that its wholly-owned subsidiary, Guangzhou Apichope Pharmaceutical Co., Ltd., has received acceptance for its clinical trial application for the self-developed novel drug APH03867 tablets from the National Medical Products Administration, along with the corresponding acceptance notice.<br><br>APH03867 tablets are a new type of oral, non-peptide small molecule URAT1 inhibitor (Urate Transporter 1) independently developed by the company. By inhibiting the activity of URAT1 in the kidneys, the drug blocks the reabsorption of uric acid in the renal tubules, increases uric acid excretion, and effectively reduces serum uric acid levels. It is intended for the improvement of hyperuricemia and gout symptoms.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apichope Pharmaceutical's Subsidiary Sees Clinical Trial Application for Novel Drug APH03867 Accepted</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApichope Pharmaceutical's Subsidiary Sees Clinical Trial Application for Novel Drug APH03867 Accepted\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-18 12:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>An announcement from <b>Apichope Pharmaceutical Group Co.,Ltd.</b> (<b>ASX: 300723</b>) reveals that its wholly-owned subsidiary, Guangzhou Apichope Pharmaceutical Co., Ltd., has received acceptance for its clinical trial application for the self-developed novel drug APH03867 tablets from the National Medical Products Administration, along with the corresponding acceptance notice.<br><br>APH03867 tablets are a new type of oral, non-peptide small molecule URAT1 inhibitor (Urate Transporter 1) independently developed by the company. By inhibiting the activity of URAT1 in the kidneys, the drug blocks the reabsorption of uric acid in the renal tubules, increases uric acid excretion, and effectively reduces serum uric acid levels. It is intended for the improvement of hyperuricemia and gout symptoms.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159992","symbol_name":"创新药","start_time":0,"source_url":"","article_id":"1177714897","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177714897","pubTimestamp":1781755772,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"An announcement from Apichope Pharmaceutical Group Co.,Ltd. (ASX: 300723) reveals that its wholly-owned subsidiary, Guangzhou Apichope Pharmaceutical Co., Ltd., has received acceptance for its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","300723":"一品红","BK1161":"生物科技","BK1574":"生物医药B类股","BK0239":"医药制造","06978":"永泰生物-B"},"translate_title":"Apichope制药子公司新药APH03867临床试验申请获受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"300723":1,"06978":1},"content_text":"An announcement from Apichope Pharmaceutical Group Co.,Ltd. (ASX: 300723) reveals that its wholly-owned subsidiary, Guangzhou Apichope Pharmaceutical Co., Ltd., has received acceptance for its clinical trial application for the self-developed novel drug APH03867 tablets from the National Medical Products Administration, along with the corresponding acceptance notice.APH03867 tablets are a new type of oral, non-peptide small molecule URAT1 inhibitor (Urate Transporter 1) independently developed by the company. By inhibiting the activity of URAT1 in the kidneys, the drug blocks the reabsorption of uric acid in the renal tubules, increases uric acid excretion, and effectively reduces serum uric acid levels. It is intended for the improvement of hyperuricemia and gout symptoms.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}